The 'War on Cancer' is 40 years old today, and the Wall Street Journal's Health Blog spoke with American Society of Clinical Oncology President Michael Link about those four decades and what remains to be done. "The most important thing to point out is the return on investment in lab research," Link tells the Health Blog, citing advances in understanding the molecular nature of cancer and drugs like Gleevec to target specific cancers.
The Forty Years' War
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.